Rydex Srs Trust Biotechnology Fd: (MF: RYOIX)
NAV
$54.17
NAV Day Change
0.53 (0.99%)
May 21 06:06 PM ET
General Information As Of 04/30/13
| %Yield | 0.00 |
| %SEC Yield | NA |
| %YTD Return (as of 04/30/13) | 26.11 |
| Objective* | Equity - Sector Health |
| Peer* | HL MG |
Portfolio Statistics
| %Unrealized Gain YTD | 37.65 |
| Net Assets (Mil $) 04/30/2013 | 165.54 |
| %Turnover 04/30/2013 | 333.00 |
Fees
| %Max Sales Load | NA |
| %Min Sales Load | NA |
| %Max Deferred Load | NA |
Expenses
| %Max 12b-1 Fee | 0.00 |
| %Max Management Fee | 0.85 |
| Redemption Fee | NA |
| Expense Ratio | 1.34 |
Allocation
| Large Growth | 56.63 |
| Large Value | 0.00 |
| Small Growth | 0.00 |
| Small Value | 0.00 |
| Foreign Stock | 0.00 |
| Emerging Market | 0.00 |
| Precious Metal | 0.00 |
| Intermediate Bond | 0.00 |
| Foreign Bond | 0.00 |
| High Yield Bond | 0.00 |
Portfolio Information
Composition
| As of 12/31/2012 | %of Net Assets |
| Stock | 99.96 |
| Cash | 8.21 |
| Bonds | 0.00 |
| Preferred | 0.00 |
| Convertibles | 0.00 |
| Foreign Stock | 5.05 |
| Foreign Bonds | 0.00 |
| Hedge | 0.00 |
| Other | -8.17 |
Sector / Country Weightings
| As of 04/30/2013 | % of Portfolio |
|---|---|
| Health | 67.24 |
| Services | 18.25 |
| Technology | 8.15 |
| Industrial Cyclical | 6.32 |
| Other | 0.04 |
Portfolio Holdings
| Top Equity Holdings (As of 12/31/2012) | % of Portfolio | Value (Mil$) |
|---|---|---|
| AMGEN INC | 8.76 | 15.18 |
| GILEAD SCIENCES INC | 8.06 | 13.97 |
| BIOGEN IDEC INC | 6.32 | 10.95 |
| CELGENE CORP | 6.25 | 10.83 |
| ALEXION PHARMACEUTICALS I | 4.62 | 8.01 |
| REGENERON PHARMACEUTICALS | 4.36 | 7.55 |
| VERTEX PHARMACEUTICALS IN | 3.25 | 5.62 |
| LIFE TECHNOLOGIES CORP | 3.10 | 5.38 |
| ILLUMINA INC | 2.95 | 5.11 |
Contact Information
| Family | Security Funds |
| Addrerss | 1 Security Benefit Place Topeka, KS 66636 |
| Phone | 800 888-2461 |
Zacks Premium Research
Zacks Mutual Fund Rank: 1 - Strong Buy 
| #1 |
Fund Description
The fund was incepted in April 1998 and is managed by Rydex Global Advisors. The fund seeks capital appreciation by investing in companies that are involved in the biotechnology industry, including companies involved in research and development, genetic or other biological engineering, and in the design, manufacture, or sale of related biotechnology products or services (biotechnology companies). The fund invests substantially all of its assets in equity securities of biotechnology companies that are traded in the United States. The fund may also engage in futures and options transactions, purchase ADRs and U.S. government securities, and enter into repurchase agreements. Dividends and capital gains, if any, are distributed annually.
Stock Holding % of Net Assets
| As Of | 12/31/2012 |
| Total Issues | 44 |
| Avg. P/E | 41.55 |
| Avg. P/Book | 5.58 |
| Avg. EPS Growth | 16.05 |
| Avg. Market Value (Mil $) | 18,734 |
Risk
| 3 Year | 5 Year | 10 Year | |
|---|---|---|---|
| Beta | 1.05 | 0.82 | 0.88 |
| Alpha | 10.85 | 15.47 | 6.51 |
| R Squared | 0.61 | 0.46 | 0.42 |
| Std. Dev. | 20.06 | 22.84 | 19.95 |
| Sharpe | 1.34 | 0.96 | 2.00 |
Shareholder Information
| Manager | Team Managed |
| Since | NA |
| Manager Rating | NA |
| Inception Date | 04/01/1998 |
| Shareholders | NA |
| Dividends Paid | A |
| Minimum Initial Investment | $2,500 |
| Minimum Subsequent Investment | $0 |
| IRA Minimum | $1000 |
| IRA Available | Y | Check Writing | N | Phone Invest | Y |
| Phone Exchange | Y | Phone Redeem | Y | Auto Invest | Y |
| Wire Redeem | Y | Wire Fee | Y | Wire Transfer | Y |
Zacks Commentary for RYOIX
Zacks Blog: Top 5 Zacks #1 Ranked Healthcare Mutual Funds
May 16, 2013
Zacks Blog: Top 5 Best Performing Healthcare Mutual Funds Year to Date
Jan 24, 2013
Zacks Blog: Top 5 Zacks #1 Ranked Healthcare Mutual Funds
Jan 02, 2013
Zacks Blog: Top 5 Best Performing Healthcare Mutual Funds Year to Date
Nov 28, 2012
Zacks Blog: Top 5 Zacks #1 Ranked Healthcare Mutual Funds
Nov 23, 2012
